Project Grant R01HL187647
Award Date 8/24/26
Completion Date 5/31/31
Dollars Obligated $546K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $554,085 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the interconnection between actin dynamics and cardiac metabolic homeostasis, specifically examining how defects in mitochondrial clearance contribute to heart failure and neuromuscular diseases including Parkinson's disease. The research explores the spatiotemporal regulation of...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $773,466 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 3, 2026, to investigate CXCL5-CXCR2 signaling mechanisms in macrophage cholesterol efflux and atherosclerosis prevention. The research integrates systems biology, pharmacology, and atherosclerosis expertise across three aims: elucidating CXCL5-CXCR2 signaling mechanisms using multi-omics and CRISPR-Cas9 in human...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,924 on July 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837) to support research on cell surface localization of Factor VIII mimetic therapy for hemophilia A treatment. The award funds a five-year project running through June 30, 2031, with work performed in Chapel Hill, North Carolina. The research addresses hemophilia A, an inherited bleeding disorder caused...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $693,182 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific mechanisms of congenital heart disease through analysis of the DDX3X gene. The award funds research examining how the X-linked dead-box helicase 3 gene (DDX3X) regulates sex differences in cardiac development and function. The research includes creating conditional DDX3X...
- The National Heart, Lung, and Blood Institute awarded Duke University $100,228 on December 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered innervated human heart tissues for in vitro studies of cardiac injury response. The recipient will develop and characterize a compartmentalized three-dimensional coculture model of human cardiobundles—engineered cardiac tissues derived from human induced pluripotent stem cells—innervated with sympathetic...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $459,838 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025 through July 31, 2027. This award supports software development and community engagement activities for the Cardinal open-source software infrastructure, which provides a unified computational platform for simulating all major aspects of...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $165,260 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research on the role of the small GTPase Rap1 and environmental cues in regulating adhesion and cytoskeletal dynamics in migrating platelets. The research addresses molecular mechanisms underlying platelet migration at sites of inflammation, with potential applications to immunothrombosis...